317 related articles for article (PubMed ID: 30809293)
1. Evaluation of [
Vermeulen K; Naus E; Ahamed M; Attili B; Siemons M; Luyten K; Celen S; Schymkowitz J; Rousseau F; Bormans G
Theranostics; 2019; 9(2):554-572. PubMed ID: 30809293
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [
Vermeulen K; Ahamed M; Luyten K; Bormans G
Nucl Med Biol; 2019; 74-75():1-11. PubMed ID: 31421440
[TBL] [Abstract][Full Text] [Related]
3. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma.
Barbagallo I; Parenti R; Zappalà A; Vanella L; Tibullo D; Pepe F; Onni T; Li Volti G
Acta Histochem; 2015 Oct; 117(8):705-11. PubMed ID: 26493719
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of [
Vermeulen K; Cools R; Briard E; Auberson Y; Schoepfer J; Koole M; Cawthorne C; Bormans G
ACS Chem Neurosci; 2021 Oct; 12(20):3915-3927. PubMed ID: 34597516
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
7. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G
Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158
[TBL] [Abstract][Full Text] [Related]
8. Radiosynthesis and preclinical evaluation of [
Cools R; Vermeulen K; Narykina V; Leitao RCF; Bormans G
EJNMMI Radiopharm Chem; 2023 Jan; 8(1):2. PubMed ID: 36715827
[TBL] [Abstract][Full Text] [Related]
9. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
10. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitor NMS-E973 exerts the anticancer effect against glioblastoma via induction of PUMA-mediated apoptosis.
Sun L; Yang S; Chi G; Jin X
Onco Targets Ther; 2018; 11():1583-1593. PubMed ID: 29593424
[TBL] [Abstract][Full Text] [Related]
12. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.
Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS
J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880
[TBL] [Abstract][Full Text] [Related]
13. Radiosynthesis, biological evaluation and preliminary microPET study of
Kang J; Young Lee J; Taş İ; More KN; Kim H; Park JH; Chang DJ
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3658-3664. PubMed ID: 30528977
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
15. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
17. Comparative preclinical evaluation of
Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
[TBL] [Abstract][Full Text] [Related]
18. Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model.
Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Life Sci; 2002 Jan; 70(7):791-8. PubMed ID: 11833741
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
20. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
